Treatment with recombinant human activated protein C: one size does not fit all
- PMID: 21247509
- PMCID: PMC3222020
- DOI: 10.1186/cc9375
Treatment with recombinant human activated protein C: one size does not fit all
Abstract
Protein C plays an important role in the coagulopathy associated with sepsis and probably also in the pathogenesis of sepsis-induced organ dysfunction. Plasma levels of protein C strongly correlate with clinical outcome in patients with severe sepsis. The RESPOND (Research Evaluating Serial Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa [Activated]) study shows that administration of recombinant human activated protein C in patients with severe sepsis with alternative dose regimens adjusted to plasma levels of protein C results in higher plasma levels of protein C. This may potentially translate to a better clinical outcome in patients with severe sepsis, although that was not directly shown in this trial.
© 2011 BioMed Central Ltd
Comment on
-
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).Crit Care. 2010;14(6):R229. doi: 10.1186/cc9382. Epub 2010 Dec 21. Crit Care. 2010. PMID: 21176144 Free PMC article. Clinical Trial.
References
-
- Shorr AF, Janes J, Artigas A, Tenhunen J, Wyncoll D, Mercier E, Francois B, Vincent JL, Vangerow B, Heiselman DE, Leishman AG, Zhu YE, Reinhart K. for the RESPOND Investigators. Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated) Crit Care. 2010;14:R229. doi: 10.1186/cc9382. - DOI - PMC - PubMed
-
- Anas AA, Wiersinga WJ, de Vos AF, van der Poll T. Recent insights into the pathogenesis of bacterial sepsis. Neth J Med. 2010;68:147–152. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical